The two parallel Antibody Mediated Prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition. Here we analyzed HIV-1 acquisition in AMP through the Week 104 final study visit. Against viruses considered...
A. deCamp, M. Juraska, Li Li et al.· Science Translational Medici...· 0 citations
CD4 + T cell responses are an independent correlate of COVID-19 risk among PWH with pre-existing SARS-CoV-2 immunity, and in people with HIV and hybrid immunity, CD4 + T cell responses at one month post-vaccination correlate inversely with risk of COVID-19 over 6 months.
Sharon Khuzwayo, Bo Zhang, Valentin Voillet et al.· Nature Communications· 1 citation
The relative efficacy, safety, and immunogenicity of monovalent mRNA-1273 (ancestral WA1) versus bivalent mRNA-1273.222 (ancestral plus omicron BA.4/BA.5) boosting have not been studied prospectively where HIV and SARS-CoV-2 seroprevalence are high. CoVPN 3008 (NCT05168813) was a randomized, double-blinded trial in sev...
S. Dadabhai, Taraz Samandari, Bo Zhang et al.· Research Square· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.